Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New commercial model in the works at GSK

Executive Summary

GlaxoSmithKline is jumping on the bandwagon to restructure as the sales environment shifts. CEO Andrew Witty says the company is remodeling its U.S. operations, but did not offer specifics during a third quarter earnings call Oct. 22. The firm continues to take a hit from generic competition in the U.S. and the Avandia (rosiglitazone) controversy (1"The Pink Sheet," June 16, 2008, p. 25)

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts